<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(9)</volume><submitter>Wan J</submitter><pubmed_abstract>&lt;b>Rationale:&lt;/b> Prodrug strategies that render the drug temporarily inactive through a cleavable linkage are able to modulate the physicochemical properties of drugs for adaptive nanoparticle (NP) formulation. Here we used cabazitaxel as a model compound to test the validity of our "balancing NP stability and specific drug activation" strategy. &lt;b>Methods:&lt;/b> Cabazitaxel is conjugated to hydrophobic polylactide fragments with varying chain lengths &lt;i>via&lt;/i> a self-immolation linkage, yielding polymeric prodrugs that can be reactivated by reductive agents in cells. Following a nanoprecipitation protocol, cabazitaxel prodrugs can be stably entrapped in amphiphilic polyethylene-&lt;i>block&lt;/i>-polylactide matrices to form core-shell nanotherapies with augmented colloidal stability. &lt;b>Result</pubmed_abstract><journal>Theranostics</journal><pagination>4137-4154</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7977460</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.</pubmed_title><pmcid>PMC7977460</pmcid><pubmed_authors>Qi H</pubmed_authors><pubmed_authors>Wan J</pubmed_authors><pubmed_authors>Huang L</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Jin J</pubmed_authors><pubmed_authors>Cheng J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.</name><description>&lt;b>Rationale:&lt;/b> Prodrug strategies that render the drug temporarily inactive through a cleavable linkage are able to modulate the physicochemical properties of drugs for adaptive nanoparticle (NP) formulation. Here we used cabazitaxel as a model compound to test the validity of our "balancing NP stability and specific drug activation" strategy. &lt;b>Methods:&lt;/b> Cabazitaxel is conjugated to hydrophobic polylactide fragments with varying chain lengths &lt;i>via&lt;/i> a self-immolation linkage, yielding polymeric prodrugs that can be reactivated by reductive agents in cells. Following a nanoprecipitation protocol, cabazitaxel prodrugs can be stably entrapped in amphiphilic polyethylene-&lt;i>block&lt;/i>-polylactide matrices to form core-shell nanotherapies with augmented colloidal stability. &lt;b>Result</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2025-04-25T18:39:12.143Z</modification><creation>2025-04-06T07:41:24.345Z</creation></dates><accession>S-EPMC7977460</accession><cross_references><pubmed>33754053</pubmed><doi>10.7150/thno.54066</doi></cross_references></HashMap>